Bernie Sanders Calls Lilly & Novo #pharma a"Greedy" for Raising Prices of Insulin Drugs | Pharmaguy's Insights Into Drug Industry News | Scoop.it

Despite his defeat in the primary, popular Vermont Senator Bernie Sanders continues to lend his star power to the principals of the political revolution, taking aim Tuesday at a pharmaceutical company that raised the price of a life-saving insulin drug—and Wall Street is taking notice.

Tuesday morning, Sanders criticized pharmaceutical company Eli Lilly, which raised the price of its insulin drug Homolog (sic) by 700 percent in 20 years when adjusted for inflation.

In a tweet to his 2.7 million Twitter followers, the Vermont Senator posted a Washington Post graph showing the cost of Homolog has risen from $21 to $255 since 1996. Sanders blamed “the drug industry’s greed” for profiting off those in need.